Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. （開啟新視窗）

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

出處‎: Lancet Haematol. 2023 ;10(4):e261-71.

檢索‎: PubMed 36870358

DOI碼‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ （開啟新視窗）

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. （開啟新視窗）

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

出處‎: Eur J Haematol 1996;56(5):326-8.

檢索‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 （開啟新視窗）

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. （開啟新視窗）

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

出處‎: Acta Haematol 1995;94(3):128-34.

檢索‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 （開啟新視窗）

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. （開啟新視窗）

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

出處‎: Haematologica 2006;91(8):1076-83.

檢索‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 （開啟新視窗）

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. （開啟新視窗）

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

出處‎: J Obstet Gynaecol 2007;27(1):82-3.

檢索‎: PubMed 17365469

DOI碼‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 （開啟新視窗）

The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. （開啟新視窗）

Wang SW, Badami CD, Deitch EA.

出處‎: Am Surg 2009;75(12):1175-8.

檢索‎: PubMed 19999907

https://www.ncbi.nlm.nih.gov/pubmed/19999907 （開啟新視窗）